QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 1, 2015

Primary Completion Date

September 1, 2019

Study Completion Date

September 1, 2019

Conditions
Chordoma
Interventions
OTHER

Placebo

Placebo will consist of USP-grade or equivalent 0.9% Sodium Chloride for Injection. Doses of placebo will be drawn into labeled syringes by an independent, unblinded pharmacist or designee.

BIOLOGICAL

GI-6301 Vaccine (Yeast- Brachyury)

GI-6301 Vaccine is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.

RADIATION

Radiotherapy

Standard of care

DEVICE

wGT3X-BT Actigraph

wGT3X-BT is small, non-invasive, portable watch accelerometer worn on the subject's wrist for Cycle 1 through Cycle 9

Trial Locations (1)

20892

NIH Clinical Center, Bethesda

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

NantCell, Inc.

INDUSTRY